Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality [3]

Blood

Volumn 97, Issue 7, 2001, Pages 2183-2185

  Hebart, Holger ^a   Brugger, Wolfram ^a   Grigoleit, Ulrich ^a   Gscheidle, Barbara ^a   Loeffler, Juergen ^a   Schäfer, Hansjörg ^a   Kanz, Lothar ^a   Einsele, Hermann ^a   Sinzger, Christian ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD34 ANTIGEN; FOSCARNET; GANCICLOVIR; THYMOCYTE ANTIBODY;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; INFECTION RISK; LETTER; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; STEM CELL; T LYMPHOCYTE SUBPOPULATION;

EID: 0035313365     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.7.2183     Document Type: Letter

References (9)

1. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
2. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
3. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease
4. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
5. Recovery of HLA-restricted cytomegalovirus responses after allogeneic bone marrow transplanration: Correlation with CMV disease and effect of ganciclovir prophylaxis
6. Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation
7. Increased risk of late CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T-cell responses
8. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
9. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients